• Tarsus Pharmaceuticals recently faced significantly lowered consensus earnings-per-share estimates and a low analyst ranking ahead of its June 2026 quarterly results, even as revenue was projected to increase year over year.
• This combination of weaker profit expectations and growing sales highlights a tension between top-line momentum and concerns about the company’s near-term earnings profile.
• Now we’ll examine how this sharp downward revision in earnings expectations may affect Tarsus Pharmaceuticals’ previously optimistic long-term investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Tarsus Pharmaceuticals Investment Narrative Recap

To own Tarsus Pharmaceuticals, you need to believe XDEMVY can keep building a durable, high-margin franchise while the pipeline slowly broadens the story beyond a single product. The recent sharp cut to consensus EPS ahead of the June 2026 report raises questions about how quickly that growth can translate into cleaner earnings, but it does not fundamentally alter the near term catalyst of XDEMVY uptake or the key risk around managing high commercial spending against still negative profitability.

The recent US$15,000,000 milestone payment tied to XDEMVY’s approval in China is especially relevant here, because it underscores how revenue can grow even as earnings expectations soften. That international contribution, together with rising XDEMVY sales, may help support the top line while management works through higher SG&A and an interim commercial leadership transition, both of which sit at the heart of the current earnings uncertainty.

But against that backdrop, you should be aware that if prescription growth ever slows materially...

Tarsus Pharmaceuticals' narrative projects $1.1 billion revenue and $632.5 million earnings by 2029. This requires 28.3% yearly revenue growth and about a $681 million earnings increase from -$48.3 million today.

Uncover how Tarsus Pharmaceuticals' forecasts yield a $94.11 fair value, a 59% upside to its current price.

Exploring Other Perspectives

While consensus once saw Tarsus reaching about US$988,000,000 in revenue and US$188,000,000 in earnings by 2029, the lowest analysts already stressed how payer pressure and heavier spending could quickly reshape those forecasts, reminding you that even before this earnings revision, opinion on Tarsus’s risk reward profile was far from settled.

Explore 4 other fair value estimates on Tarsus Pharmaceuticals - why the stock might be worth just $88.00!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Tarsus Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tarsus Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tarsus Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.